Genmab (GMAB)
(Delayed Data from NSDQ)
$28.24 USD
-0.11 (-0.39%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $28.24 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Balance Sheet
Fiscal Year End for Genmab AS Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4,085 | 3,161 | 3,077 | 2,463 | 1,645 |
Receivables | 718 | 857 | 541 | 415 | 448 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 4,812 | 4,018 | 3,617 | 2,879 | 2,093 |
Net Property & Equipment | 139 | 113 | 99 | 69 | 36 |
Investments & Advances | 19 | 19 | 59 | 166 | 22 |
Other Non-Current Assets | 9 | 7 | 4 | 3 | 2 |
Deferred Charges | 31 | 36 | 42 | 27 | 21 |
Intangibles | 15 | 21 | 40 | 52 | 70 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 5,124 | 4,287 | 3,918 | 3,239 | 2,270 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 8 | 0 | 0 | 0 | 11 |
Other Current Liabilities | 340 | 248 | 240 | 186 | 126 |
Total Current Liabilities | 361 | 258 | 249 | 192 | 141 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 70 | 68 | 77 | 75 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 2 | 2 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 534 | 402 | 387 | 310 | 164 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 10 | 9 | 11 | 10 | 10 |
Capital Surplus | 1,809 | 1,743 | 1,914 | 1,822 | 1,762 |
Retained Earnings | 2,762 | 2,119 | 1,594 | 1,089 | 319 |
Other Equity | 9 | 14 | 13 | 8 | 15 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4,590 | 3,886 | 3,531 | 2,929 | 2,106 |
Total Liabilities & Shareholder's Equity | 5,124 | 4,287 | 3,918 | 3,239 | 2,270 |
Total Common Equity | 4,590 | 3,886 | 3,531 | 2,929 | 2,106 |
Shares Outstanding | 660.70 | 659.60 | 657.10 | 655.40 | 650.70 |
Book Value Per Share | 6.95 | 5.89 | 5.37 | 4.47 | 3.24 |
Fiscal Year End for Genmab AS Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4,307 | 4,085 | 4,019 | 3,636 |
Receivables | NA | 681 | 718 | 793 | 703 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 15 | 8 | 10 | 7 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 5,004 | 4,812 | 4,822 | 4,346 |
Net Property & Equipment | NA | 136 | 139 | 138 | 133 |
Investments & Advances | NA | 22 | 19 | 23 | 27 |
Other Non-Current Assets | NA | 9 | 9 | 5 | 5 |
Deferred Charges | NA | 31 | 31 | 37 | 37 |
Intangibles | NA | 3 | 15 | 17 | 19 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 5,341 | 5,124 | 5,145 | 4,672 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 18 | 8 | 65 | 0 |
Other Current Liabilities | NA | 371 | 340 | 347 | 279 |
Total Current Liabilities | NA | 402 | 361 | 424 | 291 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 70 | 70 | 70 | 70 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 5 | 5 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 609 | 534 | 602 | 471 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 10 | 10 | 10 | 10 |
Capital Surplus | NA | 1,823 | 1,809 | 1,818 | 1,813 |
Retained Earnings | NA | 2,883 | 2,762 | 2,694 | 2,362 |
Other Equity | NA | 16 | 9 | 21 | 16 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 4,732 | 4,590 | 4,542 | 4,201 |
Total Liabilities & Shareholder's Equity | NA | 5,341 | 5,124 | 5,145 | 4,672 |
Total Common Equity | 0 | 4,732 | 4,590 | 4,542 | 4,201 |
Shares Outstanding | 661.30 | 661.20 | 660.70 | 660.60 | 660.30 |
Book Value Per Share | 0.00 | 7.16 | 6.95 | 6.88 | 6.36 |